Reuters logo
BRIEF-Ligand Pharmaceuticals says signed license and supply agreement via subsidiary with Meridian Laboratories​
November 13, 2017 / 1:54 PM / a month ago

BRIEF-Ligand Pharmaceuticals says signed license and supply agreement via subsidiary with Meridian Laboratories​

Nov 13 (Reuters) - Ligand Pharmaceuticals Inc

* Ligand Pharmaceuticals Inc - ‍on Nov. 10, 2017, co signed a license agreement and a supply agreement via a subsidiary with Meridian Laboratories Inc​

* Ligand Pharmaceuticals Inc - ‍Ligand could receive commercial revenue from shipment of Captisol to Meridian for clinical and commercial activities​

* Ligand Pharmaceuticals - ‍co granting Meridian exclusive right to use Captisol in Meridian’s development and commercialization of a Captisol

* Ligand Pharmaceuticals says ‍could potentially receive payments associated with certain licenses, royalties and milestone payments -SEC filing​ Source text: (bit.ly/2i9xLPu) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below